Shifting priorities at FDA means work on a specific review pathway for combination products has been superseded by implementation of the combo products provision in the 21st Century Cures Act, agency center directors said at a recent hearing in the Senate.
Testifying before the Senate Health, Education, Labor and Pensions (HELP) Committee on March 21, Device Center Director Jeffrey Shuren told Sen. Sheldon Whitehouse, D-R.I
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?